116 related articles for article (PubMed ID: 11068753)
1. Use of vaccinia virus expression vectors to investigate antigen processing and presentation.
Wherry EJ; Rajagopal D; Eisenlohr LC
Methods Mol Biol; 2001; 156():89-109. PubMed ID: 11068753
[No Abstract] [Full Text] [Related]
2. Sindbis virus-based vectors for the study of class I antigen presentation in vitro and in vivo.
Polo JM; Bergmann CC
Methods Mol Biol; 2001; 156():111-28. PubMed ID: 11068754
[No Abstract] [Full Text] [Related]
3. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells.
Jaraquemada D; Marti M; Long EO
J Exp Med; 1990 Sep; 172(3):947-54. PubMed ID: 2388037
[TBL] [Abstract][Full Text] [Related]
4. Recognition of vaccinia virus-encoded major histocompatibility complex class I antigens by virus immune cytotoxic T cells is independent of the polymorphism of the peptide transporters.
Lobigs M; Müllbacher A
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2676-80. PubMed ID: 8464875
[TBL] [Abstract][Full Text] [Related]
5. Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes.
Shen X; Wong SB; Buck CB; Zhang J; Siliciano RF
J Immunol; 2002 Oct; 169(8):4222-9. PubMed ID: 12370352
[TBL] [Abstract][Full Text] [Related]
6. Identification of overlapping class I and class II H-2d-restricted T cell determinants of influenza virus N1 neuraminidase that require infectious virus for presentation.
Wysocka M; Eisenlohr LC; Otvos L; Horowitz D; Yewdell JW; Bennink JR; Hackett CJ
Virology; 1994 May; 201(1):86-94. PubMed ID: 7513927
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of class I+, class II- hepatocytes.
Almond PS; Bumgardner GL; Chen S; Platt J; Payne WD; Matas AJ
Transplant Proc; 1991 Feb; 23(1 Pt 1):108-9. PubMed ID: 1899298
[No Abstract] [Full Text] [Related]
8. Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway.
Neumeister C; Nanan R; Cornu TI; Lüder CGK; Ter Meulen V; Naim H; Niewiesk S
J Gen Virol; 2001 Feb; 82(Pt 2):441-447. PubMed ID: 11161284
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia virus as a tool for immunologic studies.
Tatsis N; Sinnathamby G; Eisenlohr LC
Methods Mol Biol; 2004; 269():267-88. PubMed ID: 15114021
[TBL] [Abstract][Full Text] [Related]
10. No recognition of MHC class II+ cells infected with a vaccinia virus encoding influenza type A nucleoprotein by class II-restricted T cells.
Freer G; Senesi S
Immunol Lett; 1993 Jun; 36(3):305-12. PubMed ID: 8370602
[TBL] [Abstract][Full Text] [Related]
11. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
12. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.
Ikonomidis G; Paterson Y; Kos FJ; Portnoy DA
J Exp Med; 1994 Dec; 180(6):2209-18. PubMed ID: 7964496
[TBL] [Abstract][Full Text] [Related]
13. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
Herrera OB; Brett S; Lechler RI
Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
[TBL] [Abstract][Full Text] [Related]
14. Surrogate antigen processing mediated by TAP-dependent antigenic peptide secretion.
Gabathuler R; Alimonti J; Zhang QJ; Kolaitis G; Reid G; Jefferies WA
J Cell Biol; 1998 Jan; 140(1):17-27. PubMed ID: 9425150
[TBL] [Abstract][Full Text] [Related]
15. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors.
Lee SS; Eisenlohr LC; McCue PA; Mastrangelo MJ; Lattime EC
Cancer Res; 1994 Jul; 54(13):3325-8. PubMed ID: 8012943
[TBL] [Abstract][Full Text] [Related]
16. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.
Townsend A; Bastin J; Gould K; Brownlee G; Andrew M; Coupar B; Boyle D; Chan S; Smith G
J Exp Med; 1988 Oct; 168(4):1211-24. PubMed ID: 2459295
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to H-2Kd antigen expressed by recombinant vaccinia virus.
Coupar BE; Andrew ME; Boyle DB; Blanden RV
Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7879-82. PubMed ID: 3489941
[TBL] [Abstract][Full Text] [Related]
18. T cell recognition of QA-1b antigens on cells lacking a functional Tap-2 transporter.
Aldrich CJ; Waltrip R; Hermel E; Attaya M; Lindahl KF; Monaco JJ; Forman J
J Immunol; 1992 Dec; 149(12):3773-7. PubMed ID: 1460275
[TBL] [Abstract][Full Text] [Related]
19. Quantitating presentation of MHC class I-restricted antigens.
Chen W; Bennink JR; Yewdell JW
Methods Mol Biol; 2001; 156():245-54. PubMed ID: 11068765
[No Abstract] [Full Text] [Related]
20. Antigen presentation to cytotoxic T lymphocytes in vivo.
Bevan MJ
J Exp Med; 1995 Sep; 182(3):639-41. PubMed ID: 7650475
[No Abstract] [Full Text] [Related]
[Next] [New Search]
